Liver dysfunction in Pennsylvania's multitransfused hemophiliacs.
Transaminase values [alanine amino transferase (ALT) and aspartate amino transferase (AST)] and markers for hepatitis B were serially determined in 558 hemophiliacs exposed to blood products. Hepatitis B surface antigen (HBsAg) persistent for over 12 months was present in 6% of the patients. Antibody to hepatitis B surface antigen (anti-HBs) was noted in 90% of the 259 patients treated with factor VIII or IX concentrates but in only 49% of the 43 patients treated with fresh frozen plasma (FFP) or cryoprecipitate. Persistently abnormal transaminase values were noted in 31% of the patients treated with commercial concentrates but in only one (2%) of the patients exposed to cryoprecipitate or FFP. This difference continued even when the two groups of patients were matched for the amount of blood products, up to 50,000 units, which they had received in the study period. In the concentrate-treated patients, no correlation could be found between transaminase values and the number of units of factor VIII or IX they had received during the six years of the study (1973-1978).
D000293:Adolescent; D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D001793:Blood Preservation; D002648:Child; D005164:Factor IX / Q000008:administration & dosage; D005169:Factor VIII / Q000008:administration & dosage; D006467:Hemophilia A / Q000628:therapy*; D006509:Hepatitis B / Q000175:diagnosis / Q000209:etiology*; D006514:Hepatitis B Surface Antigens / Q000302:isolation & purification; D006801:Humans; D008111:Liver Function Tests / Q000379:methods; D010414:Pennsylvania; D010949:Plasma; D065227:Transfusion Reaction
D006514:Hepatitis B Surface Antigens; D005169:Factor VIII; D005164:Factor IX; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase